Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Pier 88 Investment Partners LLC

Pier 88 Investment Partners LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,090 shares of the company’s stock after selling 460 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Neurocrine Biosciences were worth $356,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of NBIX. RFP Financial Group LLC boosted its stake in shares of Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after purchasing an additional 149 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $30,000. New Covenant Trust Company N.A. purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth about $32,000. Finally, EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter worth about $35,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the topic of several analyst reports. Robert W. Baird lifted their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Raymond James restated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, Barclays lowered their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $125.51 on Thursday. Neurocrine Biosciences, Inc. has a one year low of $107.84 and a one year high of $157.98. The business’s 50-day moving average price is $118.47 and its two-hundred day moving average price is $132.93. The company has a market capitalization of $12.71 billion, a P/E ratio of 33.65 and a beta of 0.35.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.